Imidazopyrimidines, potent inhibitors of p38 MAP kinase

…, DE Cavender, GC Olini, B Fahmy, JJ Siekierka

Index: Rupert, Kenneth C.; Henry, James R.; Dodd, John H.; Wadsworth, Scott A.; Cavender, Druie E.; Olini, Gilbert C.; Fahmy, Bohumila; Siekierka, John J. Bioorganic and Medicinal Chemistry Letters, 2003 , vol. 13, # 3 p. 347 - 350

Full Text: HTML

Citation Number: 155

Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

Related Articles:

Syntheses and structure–activity relationships for some triazolyl p38α MAPK inhibitors

[Seerden, Jean-Paul G.; Leusink-Ionescu, Gabriela; Leguijt, Robin; Saccavini, Catherine; Gelens, Edith; Dros, Bas; Woudenberg-Vrenken, Titia; Molema, Grietje; Kamps, Jan A.A.M.; Kellogg, Richard M. Bioorganic and Medicinal Chemistry Letters, 2014 , vol. 24, # 5 p. 1352 - 1357]

Synthesis and biological activities of 4-phenyl-5-pyridyl-1, 3-thiazole derivatives as p38 MAP kinase inhibitors

[Chemical and Pharmaceutical Bulletin, , vol. 53, # 4 p. 410 - 418]

Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase

[Bioorganic and Medicinal Chemistry Letters, , vol. 20, # 8 p. 2634 - 2638]

Exploring the Binding Proteins of Glycolipids with Bifunctional Chemical Probes

[Angewandte Chemie - International Edition, , vol. 52, # 33 p. 8551 - 8556 Angew. Chem., , vol. 125, # 33 p. 8713 - 8718,6]

More Articles...